急性心肌梗死患者血清代谢标志物筛选的研究进展

Research Progress in Screening of Serum Metabolic Markers in Patients with Acute Myocardial Infarction

急性心肌梗死(AMI)是指冠状动脉病变导致的心肌缺血、缺氧和坏死损伤,患者大多存在糖类、脂质或氨基酸代谢异常,因此将机体代谢形成的中间体或产物作为标志物可为临床预防、诊断和治疗疾病提供参考。代谢组学是一门针对体液中低分子量代谢物进行检测和分析的新型技术,采用高通量检测和数据处理定量分析代谢过程中的组群指标,可以从代谢层面反映AMI病理生理机制。因此,筛选对AMI诊断具有良好参考价值的血清标志物具有重要意义。

Acute myocardial infarction(AMI)refers to myocardial ischemia,hypoxia or necrosis damage caused by coronary artery disease,and it is manifested as abnormal metabolism of carbohydrates,lipids or amino acids in most patients,thus the intermediates or products formed by the body′s metabolism as markers can provide references for the clinical prevention,diagnosis and treatment of the disease.Metabolomics is a new technology for the detection and analysis of low molecular weight metabolites in body fluids,which adopts quantitative analysis of group indicators in the metabolic process by high-throughput detection and data processing to reflect the pathophysiological mechanism of AMI from the metabolic level.Therefore,it is of great significance to screen serum markers with good reference value for AMI diagnosis.